Home › Companies › Castle Biosciences, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Castle Biosciences, Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 28, 2026: 6 items on Castle Biosciences, Inc.’s Form 8-K, filed May 29, 2026: 3 elected · 3 approved.
Significant dissent: 3 directors (36.3%, 31.5%, 30.9% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Castle Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Castle Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Ellen Goldberg | 15,455,265 | -- | -- | 7,118,166 | 2,415,788 | 68% | Elected | — |
| Elect Director: Miles D. Harrison | 15,607,369 | -- | -- | 6,966,062 | 2,415,788 | 69% | Elected | — |
| Elect Director: Tiffany P. Olson | 14,380,655 | -- | -- | 8,192,776 | 2,415,788 | 64% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 24,531,366 | 445,666 | 12,187 | -- | -- | 98% | Approved | — |
| 3. Approval of the Compensation of the Company's Named Executive Officers | 21,280,180 | 1,281,394 | 11,857 | -- | 2,415,788 | 94% | Approved | — |
| 4. Approval of the Company's Non-Employee Director Compensation Policy | 21,394,330 | 1,130,133 | 48,968 | -- | 2,415,788 | 95% | Approved | — |
Source: Castle Biosciences, Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
230 asset managers disclosed a vote on at least one Castle Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
68% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Ellen Goldberg
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Ellen Goldberg”): 15,455,265 for, 7,118,166 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 6,841,135 for, 2,362,159 withheld, 18,348 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,021,364 | 0 | 2,546 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 0 | 650,376 | Mixed |
| Principal | 0 | 0 | 0 | 754,854 | Withhold |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 336,242 | Withhold |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 147,121 | Withhold |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 75,614 | 0 | 0 | 53,033 | Mixed |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 123,000 | Withhold |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 78,975 | Withhold |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 0 | 63,600 | Withhold |
| Equitable | 47,404 | 0 | 0 | 16,020 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 46,342 | Withhold |
| Lincoln Financial | 24,259 | 0 | 0 | 19,135 | Mixed |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Miles D. Harrison
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Miles D. Harrison”): 15,607,369 for, 6,966,062 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 6,843,821 for, 2,362,003 withheld, 15,817 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,894 | 0 | 15 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 0 | 650,376 | Mixed |
| Principal | 0 | 0 | 0 | 754,854 | Withhold |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 336,242 | Withhold |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 147,121 | Withhold |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 75,622 | 0 | 0 | 53,025 | Mixed |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 123,000 | Withhold |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 78,975 | Withhold |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 0 | 63,600 | Withhold |
| Equitable | 47,404 | 0 | 0 | 16,020 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 46,342 | Withhold |
| Lincoln Financial | 24,259 | 0 | 0 | 19,135 | Mixed |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect the three Class I director nominees listed below to hold office until the 2029 Annual Meeting of Stockholders: Tiffany P. Olson
Castle Biosciences, Inc.’s own tally for this item (“Elect Director: Tiffany P. Olson”): 14,380,655 for, 8,192,776 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 6,573,359 for, 2,497,748 withheld, 150,534 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,020,164 | 0 | 2,548 | 1,198 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 698,824 | 0 | 0 | 650,376 | Mixed |
| Principal | 0 | 0 | 0 | 754,854 | Withhold |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 336,242 | Withhold |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 147,121 | Withhold |
| EA Series Trust | 0 | 0 | 132,184 | 0 | Abstain |
| State Street | 67 | 0 | 0 | 128,580 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 123,000 | Withhold |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 78,975 | Withhold |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 0 | 0 | 0 | 63,600 | Withhold |
| Equitable | 47,404 | 0 | 0 | 16,020 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 46,342 | Withhold |
| Lincoln Financial | 4,859 | 0 | 0 | 38,535 | Mixed |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 93.8% for (May 22, 2025 meeting) ▲ 0.5 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.
Castle Biosciences, Inc.’s own tally for this item (“3. Approval of the Compensation of the Company's Named Executive Officers”): 21,280,180 for, 1,281,394 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchan…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,906 | 3 | 0 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 1,349,200 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 336,242 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 147,121 | 0 | 0 | 0 | For |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 128,647 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 123,000 | 0 | 0 | 0 | For |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 0 | 78,975 | 0 | 0 | Against |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 63,600 | 0 | 0 | 0 | For |
| Equitable | 63,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 46,342 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,394 | 0 | 0 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Fund voting reports, all 72 managers: 9,157,087 for, 78,978 against, 1,239 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 2,758,335 | 0 | 0 | 0 | For |
| Portolan Capital Management, LLC | 1,350,283 | 0 | 0 | 0 | For |
| BlackRock | 1,276,747 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 1,117,727 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 728,100 | 0 | 0 | 0 | For |
| Allianz | 0 | 666,541 | 0 | 0 | Against |
| State Street | 651,348 | 0 | 0 | 0 | For |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 525,260 | 0 | 0 | 0 | For |
| Nuveen | 491,500 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 454,225 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 310,738 | 19,012 | 0 | 0 | Mixed |
| Renaissance | 270,542 | 0 | 0 | 0 | For |
| PALISADE CAPITAL MANAGEMENT, LP | 252,434 | 0 | 0 | 0 | For |
| Charles Schwab | 241,880 | 0 | 0 | 0 | For |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 233,046 | 0 | 0 | Against |
| AIGH Capital Management LLC | 226,741 | 0 | 0 | 0 | For |
| Vanguard | 225,029 | 0 | 0 | 0 | For |
| Northern Trust | 220,803 | 0 | 0 | 0 | For |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 162,948 | 0 | 0 | 0 | For |
| Allspring | 160,663 | 0 | 0 | 0 | For |
| DE Shaw | 160,240 | 0 | 0 | 0 | For |
| Two Sigma | 134,672 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 123,000 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 119,920 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 118,316 | 0 | 0 | 0 | For |
Institutional-manager reports, all 179 managers: 13,563,841 for, 1,164,863 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve our non-employee director compensation policy.
Castle Biosciences, Inc.’s own tally for this item (“4. Approval of the Company's Non-Employee Director Compensation Policy”): 21,394,330 for, 1,130,133 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of the Company's Non-Employee Director Compensation Policy The Company's stockholders approved the Company's non-employee director compensation policy as described in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 76 asset managers below reported 9,162,723 for, 109,387 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,906 | 3 | 0 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 1,349,200 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 336,242 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 147,121 | 0 | 0 | 0 | For |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 128,647 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 123,000 | 0 | 0 | 0 | For |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 103,702 | 0 | 0 | Against |
| American Century | 78,975 | 0 | 0 | 0 | For |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 63,600 | 0 | 0 | 0 | For |
| Equitable | 63,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 46,342 | 0 | 0 | 0 | For |
| FORMULA GROWTH LTD | 46,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,394 | 0 | 0 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
Showing the 25 largest of 76 asset managers. All 76 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Prior year: 99.9% for (May 22, 2025 meeting) ▼ 1.7 pts
Description as filed by funds: To ratify the selection of KPMG LLP by the Audit Committee of our Board of Directors as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Castle Biosciences, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 24,531,366 for, 445,666 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company's Board of Directors as the Company's independent registered public accounting firm for the fiscal year ending December …”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 74 asset managers below reported 9,222,564 for, 1 against, 1,239 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,023,908 | 1 | 0 | 0 | For |
| BlackRock | 1,561,151 | 0 | 0 | 0 | For |
| Fidelity | 1,349,200 | 0 | 0 | 0 | For |
| Principal | 754,854 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 448,328 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 386,425 | 0 | 0 | 0 | For |
| TIAA | 358,474 | 0 | 0 | 0 | For |
| Dimensional | 336,242 | 0 | 0 | 0 | For |
| BUFFALO FUNDS | 264,287 | 0 | 0 | 0 | For |
| Charles Schwab | 241,865 | 0 | 0 | 0 | For |
| Allspring | 147,121 | 0 | 0 | 0 | For |
| EA Series Trust | 132,184 | 0 | 0 | 0 | For |
| State Street | 128,647 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 123,000 | 0 | 0 | 0 | For |
| Nuveen | 107,524 | 0 | 0 | 0 | For |
| Goldman Sachs | 103,702 | 0 | 0 | 0 | For |
| American Century | 78,975 | 0 | 0 | 0 | For |
| PRINCIPAL VARIABLE CONTRACTS FUNDS INC | 63,600 | 0 | 0 | 0 | For |
| Equitable | 63,424 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 46,712 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 46,342 | 0 | 0 | 0 | For |
| Lincoln Financial | 43,394 | 0 | 0 | 0 | For |
| Putnam | 37,658 | 0 | 0 | 0 | For |
| JPMorgan | 36,830 | 0 | 0 | 0 | For |
| Hartford | 31,224 | 0 | 0 | 0 | For |
Showing the 25 largest of 74 asset managers. All 74 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 30,295,965 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.68% |
| 2 | BlackRock | 5.15% |
| 3 | Fidelity | 4.45% |
| 4 | Principal | 2.49% |
| 5 | WASATCH FUNDS TRUST | 1.48% |
| 6 | MUTUAL FUND SERIES TRUST | 1.28% |
| 7 | TIAA | 1.18% |
| 8 | Dimensional | 1.11% |
| 9 | BUFFALO FUNDS | 0.87% |
| 10 | Charles Schwab | 0.80% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 9.10% |
| 2 | Portolan Capital Management, LLC | 4.46% |
| 3 | BlackRock | 4.21% |
| 4 | PRINCIPAL GLOBAL INVESTORS | 3.69% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.40% |
| 6 | Allianz | 2.20% |
| 7 | State Street | 2.15% |
| 8 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1.73% |
| 9 | Nuveen | 1.62% |
| 10 | WASATCH ADVISORS LP | 1.50% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 2,982,946 | 9.85% | Form 13F, quarter ended March 31, 2026 |
| RTW Investments, LP | 2,758,335 | 9.10% | Schedule 13G, filed May 15, 2026 |
| Vanguard Group | 2,199,829 | 7.26% | Form 13F, quarter ended March 31, 2026 |
| Portloan Capital Management, LLC | 1,611,099 | 5.32% | Proxy statement (DEF 14A), table as of March 20, 2026 |
| Principal Financial Group, Inc. | 1,585,639 | 5.23% | Proxy statement (DEF 14A), table as of March 20, 2026 |
| Dimensional Fund Advisors | 1,039,761 | 3.43% | Form 13F, quarter ended March 31, 2026 |
| Derek J. Maetzold | 821,041 | 2.71% | Proxy statement (DEF 14A), table as of March 20, 2026 |
| State Street | 769,079 | 2.54% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 532,800 | 1.76% | Form 13F, quarter ended March 31, 2026 |
| Millennium Management | 353,319 | 1.17% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 30,295,965 shares outstanding, as reported by Castle Biosciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Castle Biosciences, Inc.'s shareholder meeting held May 28, 2026, in the 2025-2026 proxy season, 230 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,603 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — Castle Biosciences, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Castle Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Castle Biosciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Castle Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Castle Biosciences (CSTL) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/castle-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.